Clostridium difficile, a Gram-positive, spore-forming, anaerobic bacterium, is the main causative agent of hospital-acquired diarrhoea worldwide. In addition to metronidazole and vancomycin, rifaximin, a rifamycin derivative, is a promising antibiotic for the treatment of recurring C. difficile infections (CDI). However, exposure of C. difficile to this antibiotic has led to the development of rifaximin-resistance due to point mutations in the b-subunit of the RNA polymerase (rpoB) gene. In the present study, 348 C. difficile strains with known PCR-ribotypes were investigated for respective single nucleotide polymorphisms (SNPs) within the proposed rpoB hot-spot region by using high-resolution melting (HRM) analysis. This method allows the detection of SNPs by comparing the altered melting behaviour of dsDNA with that of wild-type DNA. Discrimination between wild-type and mutant strains was enhanced by creating heteroduplexes by mixing sample DNA with wild-type DNA, leading to characteristic melting curve shapes from samples containing SNPs in the respective rpoB section. In the present study, we were able to identify 16 different rpoB sequence-types (ST) by sequencing analysis of a 325 bp fragment. The 16 PCR STs displayed a total of 24 different SNPs. Fifteen of these 24 SNPs were located within the proposed 151 bp SNP hot-spot region, resulting in 11 different HRM curve profiles (CP). Eleven SNPs (seven of which were within the proposed hot-spot region) led to amino acid substitutions associated with reduced susceptibility to rifaximin and 13 SNPs (eight of which were within the hot-spot region) were synonymous. This investigation clearly demonstrates that HRM analysis of the proposed SNP hot-spot region in the rpoB gene of C. difficile is a fast and cost-effective method for the identification of C. difficile samples with reduced susceptibility to rifaximin and even allows simultaneous SNP subtyping of the respective C. difficile isolates.
INTRODUCTION
Clostridium difficile, a spore-forming, Gram-positive bacterium, is the most frequently identified causative agent of hospital-acquired diarrhoea and pseudomembranous colitis (Wiström et al., 2001) . Numerous C. difficile outbreaks have been caused by strains of PCR ribotype 027, REA (restriction endonuclease analysis) type BI and NAP1 (North American pulsed-field type 1), as well as toxinotype III, which is said to lead to more severe disease and higher mortality rate compared to other C. difficile strains (Kuijper et al., 2006) . The main antibiotics used for treatment of C. difficile infection (CDI) are metronidazole and vancomycin (Kuijper et al., 2006) . In addition, a promising antibiotic for the treatment of CDI is rifaximin, a rifamycin derivative. The mechanism of action of rifamycin is to inhibit the elongation of 2 or 3 nt RNA transcripts at the 59 end by binding the RNA polymerase holoenzyme (Campbell et al., 2001) . Recently, four working groups have reported C. difficile strains with reduced susceptibility to rifaximin due to SNPs within the encoding gene for the b-subunit of the RNA polymerase (rpoB) (O'Connor et al., 2008; Curry et al., 2009; Huang et al., 2010; Huhulescu et al., 2011) .
An accurate method for complete genotyping of most single nucleotide polymorphisms (SNPs) is high-resolution melting (HRM) analysis (Liew et al., 2004) where DNA amplification takes place in the presence of a fluorescent dye that attaches only to dsDNA (Wittwer et al., 2003) . During a subsequent melting step, denaturation of dsDNA occurs accompanied by reduction of the emitted fluorescence, resulting in characteristic differences measured by the LightCycler 480 software (Roche Diagnostics).
The aim of the present study was to develop an assay for the fast identification of SNPs in a proposed hot-spot region of the rpoB gene, leading to reduced rifaximin susceptibility in C. difficile by applying HRM.
METHODS
Strains used in this study. A total of 348 C. difficile isolates of different PCR-ribotypes (Table 1) were obtained from the reference strain collection of the Austrian national C. difficile reference centre, which included 25 strains from the ECDC strain collection, 50 strains from the Leeds University Hospital (UK), two strains from the Public Health Laboratory Maribor (Slovenia), 242 clinical isolates (129 of which were previously described by Indra et al., 2008) , and 29 strains from the CDIFFGEN strain collection.
Rifaximin susceptibility testing of the 348 C. difficile samples was performed in a previous study using a rifaximin broth microdilution test (Huhulescu et al., 2011) . Due to the lack of CLSI or EUCAST MIC breakpoints for rifaximin against C. difficile we interpreted samples showing an MIC .32 mg ml 21 as having reduced in vitro susceptibility as suggested by Huhulescu et al. (2011) . We investigated the 70 samples displaying reduced rifaximin susceptibility and the 278 samples that were rifaximin susceptible by using sequence analysis and HRM analysis for the detection of SNPs within the rpoB gene.
Capillary gel electrophoresis-based ribotyping of C. difficile isolates. DNA was extracted from cultures using the MagNA Pure Compact system (Roche Diagnostics) according to the manufacturer's instructions to a final volume of 50 ml. For capillary gel electrophoresisbased PCR ribotyping, primers 16S (59-GTGCGGCTGGATCACC-TCCT-39) and 23S (59-CCCTGCACCCTTAATAACTTGACC-39) were used. The 16S primer was labelled at the 59 end with either carboxyfluorescein (FAM), hexachlorofluorescein (HEX) or tetrachlorofluorescein (TET). Reactions contained 1.5 ml sample DNA, 25 ml HotStarTaq Master Mix (Qiagen), 0.3 ml (10 pmol ml 21 ) each primer and 22.9 ml of PCR-grade water. PCR was performed in a standard thermocycler (Analytic Jena) using the following programme: 95 uC for 15 min, followed by 17 cycles of 95 uC for 1 min, 61 uC for 1 min and 72 uC for 1 min, and a final step at 72 uC for 30 min. PCR products were sequenced by using an ABI 310 Genetic Analyzer with a 41 cm capillary loaded with POP4 gel (Applied Biosystems). The samples were injected at 5 kV over 5 s with a total running time of 30 min at 15 kV run voltage. As an internal marker for each sample, a 50-625 bp TAMRA ladder (Chimerx) was used. Data analysis was performed by using Peak Scanner software 1.0 (Applied Biosystems).
Sequencing of the partial rpoB. All C. difficile samples were investigated for the occurrence of SNPs within a 325 bp fragment of the rpoB gene (amino acid positions 458-565) by performing PCRs in a standard thermocycler and sequence analysis using an ABI 3130 Genetic Analyzer as described previously (Huhulescu et al., 2011) .
Briefly, DNA was isolated using the MagNA Pure Compact system (Roche Diagnostics) according to the manufacturer's instructions and eluted to a final volume of 50 ml. The primer pair RifFOR (59-CAAGATATGGAAGCTATAAC-39) and RifREVlang (59-GTGATTC-TATAAATCCAAATTC-39) was used in PCRs containing 25 ml HotStar Taq Master Mix (Qiagen), 5 ml (5 pmol ml 21 ) each primer, 13 ml PCR grade water and 2 ml sample DNA. DNA amplification was performed in a standard thermocycler using the following programme: 96 uC for 15 min, followed by 30 cycles of 94 uC for 1 min, 52 uC for 1 min and 72 uC for 1 min, with a final step at 72 uC 10 min. PCR products were purified with exonuclease I and shrimp alkaline phosphatase (Fermentas) according to the supplier's instructions.
Sequencing PCRs were performed using a BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems), each reaction containing 2 ml Terminator Ready Reaction Mix, 1 ml sequencing buffer (Applied Biosystems), 4 ml PCR grade water, 1 ml RifFOR or RifREVlang primer (10 pmol 21 ) and 2 ml DNA, in a standard thermocycler with the following programme: 96 uC for 1 min, followed by 30 cycles of 96 uC for 20 s, 50 uC for 20 s and 60 uC for 4 min. For dye terminator cleanup, PCR products were purified with Centri Sep 96-well plates or Centri Sep 8 well strips (Applied Biosystems) according to the manufacturer's instructions. Samples were analysed in an ABI 3130 Genetic Analyzer (Applied Biosystems) with 36 cm capillary loaded with POP7 gel (Applied Biosystems). Data analysis was performed by using Kodon (Applied Maths) version 3.5. Sequences were aligned to the rpoB sequence of a reference wild-type C. difficile strain (CD630; GenBank accession number NC_009089), which was obtained from the NCBI database.
HRM analysis of the SNP hot-spot region in rpoB. For HRM analysis a 151 bp fragment of rpoB (amino acid positions 469-518) was amplified using the primers RifFORlang (59-GTTAACATAA-GACCAGTTTC-39) and RifREV (59-CTCTTTCTCTTGAAAGACC-39). Each HRM reaction mixture contained 2.4 ml MgCl 2 (25 mM), 10 ml LightCycler 480 HRM Master mix (Roche Diagnostics), 2 ml each primer (10 pmol ml 21 ) and 0.6 ml PCR-grade water. To generate artificial heterozygotes, wild-type and sample DNA were mixed in a ratio of 1 : 6 (0.5 ml wild-type DNA and 2.5 ml sample DNA) and PCR grade water was used as a negative control.
PCR and melting-curve analysis was performed using the LightCycler 480 System (Roche Diagnostics) with following conditions: preincubation at 95 uC for 10 min, followed by 45 cycles of 95 uC for 10 s, 52 uC for 20 s and 72 uC for 20 s. After amplification, the melting curve was produced by heating samples up to 95 uC for 1 min and subsequent cooling to 40 uC for 1 min. HRM data were obtained at a rate of 25 acquisitions per uC. Data were analysed with the LightCycler 480 gene scanning software version 1.5 with default settings for sensitivity set to 0.30 and temperature shift set to threshold of 5. The pre-melt normalization ranged from 73.16 to 74.12 and the post-melt normalization ranged from 81.44 to 82.70. All samples were tested in triplicate and wildtype samples were used as the baseline in difference plots.
RESULTS

Sequence analysis
RpoB sequencing (Table 1) of the 348 C. difficile strains resulted in the detection of 246 (70.68 %) samples displaying the wild-type sequence (PCR ST-1) of the rpoB gene. Fifteen different PCR sequence types (excluding PCR ST-1) were determined by 23 different SNPs, four of which (L487F, H502L, S550F and S575A) had not been previously described ( Table 1 .
HRM analysis
Gene scanning was performed on DNA of 348 C. difficile isolates (spiked with wild-type DNA for the production of artificial heteroduplexes) representing 16 different PCR STs of the rpoB gene (Table 1) . After normalization, shifting and difference plotting of the obtained melting curves, 11 different HRM curve profiles (CP) were detected as demonstrated in Fig. 1 .
The HRM CP 8, characteristic of PCR sequence-type 9 (S475S+F481F+D492D+T501T+A508A+G510G+T539T+ K556K+S575A), was generated by the presence of six out of nine SNPs located within the 151 bp HRM amplicon (Tables  1, 2) , which displayed a unique melting curve shape in the difference plot. Furthermore, HRM CP-3 (PCR ST-3), which showed seven synonymous SNPs (resulting in the following amino acid substitutions: T501T+L506L+G510G+ G512G+F521F+E541E+K556K) within the 325 bp rpoB fragment in sequencing analysis, produced a clearly distinguishable melting curve in the difference plot based on the presence of four of the seven SNPs within the shorter HRM amplicon ( Table 2) .
Five rpoB sequence types could not be clearly differentiated by HRM analysis. Sequence-types characterized by a common CP (HRM CP-1) were: the rpoB wild-type PCR ST-1 and the three sequence types PCR ST-5 (A555A), PCR ST-15 (S550F) and PCR ST-16 (S550Y) as demonstrated in Table 1 . Furthermore, PCR ST-13 (H502N+A555A) showed the same HRM CP (HRM CP-6) as PCR ST-7 (H502N). PCR ST-14 (R505K+I548M) shared a common HRM CP (HRM CP-2) with PCR ST-2 (R505K).
DISCUSSION
Rifaximin was reported to be a promising drug used for a follow-up therapy after vancomycin treatment for preventing recurrent CDI (Johnson et al., 2007) . Thereby, the rapid detection of point mutations causing reduced rifaximin susceptibility in C. difficile strains is of high importance for the appropriate treatment of CDI and to ensure rapid therapeutic response. Previous studies showed that amino acid substitutions in the rpoB gene, compared with wild-type sequences, are a reliable indicator of reduced rifaximin susceptibility in C. difficile (O'Connor et al., 2008; Curry et al., 2009; Huang et al., 2010; Huhulescu et al., 2011; Miller et al., 2011) . Due to the lack of an official MIC breakpoint for rifaximin against C. difficile we suggest that samples showing an MIC .32 mg ml 21 are interpreted as reduced in vitro susceptible (Huhulescu et al., 2011) . Based on our results and previously described amino acid substitutions, we established an HRM assay using the LightCycler 480 system for the detection of SNPs within a 151 bp amplicon enclosing the proposed SNP hot-spot region of the rpoB gene in C. difficile.
Aberrations in HRM CPs of unknown samples, different from that of the wild-type (HRM CP-1), clearly indicate the presence of point mutations within the investigated DNA region, suggesting a reduced rifaximin susceptibility of the isolates. Comparison of these samples with the 11 different HRM CP standards defined for this assay provided an indication of reduced rifaximin susceptibility by the identification of the given sequence types (Fig. 1) . During this study, all samples containing SNPs within the investigated DNA region were correctly identified as sequences deviated from wild-type independent from non-synonymous or synonymous SNPs, these mutations can only be ascertained by addition of HRM CP standards.
Overall, 16 sequence-types were identified in a 325 bp region of the rpoB gene during this study, 11 of which were also identified by the described HRM assay (Table 1 ). The HRM assay design was based on the location of the most important point mutations within the rpoB gene (hot-spot region) (O'Connor et al., 2008; Curry et al., 2009; Huhulescu et al., 2011; Miller et al., 2011) and the size limitation of the HRM amplicon length (Liew et al., 2004) , leading to the exclusion of seldom found point mutations located outside of the HRM amplicon (Table 1) . Thereby, two of the 13 STs, PCR ST-15 and PCR ST-16, were not recognized by the HRM assay of the present study (Table 1) . Nevertheless, the nonsynonymous PCR sequence-type PCR ST-14 (R505K+ I548M) and PCR ST-2 (R505K) shared a common HRM CP (HRM CP-2) and could be identified, since mutation I548M was located outside of the HRM amplicon. Interestingly, ST-9 showed reduced rifaximin susceptibility (Huhulescu et al., 2011) despite displaying only synonymous point mutations in the hot-spot region (Tables 1 and 2) ; this remarkable finding could be explained by a nonsynonymous mutation at position S575A in the flanking region of the investigated rpoB fragment (data not shown). , 2011; Miller et al., 2011) , including four new substitutions (L487F, H502L, S550F and S575A) found during the course of this study (Table 3) . Only the rare mutation types S550F and S550Y at amino acid position 550, which were only identified in one sample each during this study, are located outside of the HRM amplicon. Interestingly, position 502 seems to be a locus of high frequency mutation (H502N, H502R and H502Y) . With the amino-acid-substitution H502L we detected an additional SNP at this locus.
Our data demonstrate that PCR ribotype 027 (n571) is associated with 11 of 13 detected sequence types ( Table 1) . The majority of the 71 isolates (n546) belonged to PCR ST-2 (R505K), suggesting that PCR ribotype 027 is predominantly associated with this respective sequence-type. Further analysis revealed that 42 of these 46 isolates were associated with a multicentre outbreak in three Viennese hospitals sharing similar MLVA (multiple locus variable-number tandem-repeat analysis) patterns (data not shown) (Indra et al., 2009) . These findings underpin the idea that SNP analysis is a valuable tool for additional epidemiological investigations (Mutreja et al., 2011) . Further studies will be needed to clarify the correlation between different PCR ribotypes of C. difficile and the acquisition of reduced rifaximin susceptibility.
In conclusion, the HRM assay of the present study is a rapid and specific detection method for the most common mutations in the SNP hot-spot region of the rpoB gene in C. difficile and is comparable with sequencing of the respective rpoB section, which may help eliminate the need for MIC resistance testing for non-wild-type samples.
